Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial

被引：5
|
作者：
Kim, Jaehwan [1 ,2 ,3 ]
Lee, Jongmi [1 ]
Hawkes, Jason E. [2 ]
Li, Xuan [1 ]
Kunjravia, Norma [1 ]
Rambhia, Darshna [1 ]
Cueto, Inna [1 ]
Moreno, Ariana [1 ]
Hur, Hong [4 ]
Garcet, Sandra
Zhou, Wei [5 ]
Cao, Junyue [5 ]
Krueger, James G. [1 ]
机构：
[1] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA
[2] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95816 USA
[3] Vet Affairs Northern Calif Hlth Care Syst, Dermatol Sect, Mather, CA USA
[4] Rockefeller Univ, Ctr Clin & Translat Sci, Res Bioinformat, New York, NY 10065 USA
[5] Rockefeller Univ, Lab Single Cell Genom & Populat Dynam, New York, NY 10065 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 88卷 / 02期
基金：
美国国家卫生研究院;
关键词：
dendritic cells; gene expression; IL-17; mild-to-moderate disease; psoriasis; secukinumab; type 17 T cells; T cells;
D O I：
10.1016/j.jaad.2022.04.060
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：428 / 430
页数：3
相关论文
共 50 条
  • [31] The Effect of Combination Treatment With Low-Intensity Shockwave Therapy and Tadalafil on Mild and Mild-To-Moderate Erectile Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
    Mykoniatis, Ioannis
    Pyrgidis, Nikolaos
    Zilotis, Filimon
    Kapoteli, Paraskeui
    Fournaraki, Agrippina
    Kalyvianakis, Dimitrios
    Hatzichristou, Dimitrios
    JOURNAL OF SEXUAL MEDICINE, 2022, 19 (01): : 106 - 115
  • [32] Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial
    Busse, W. W.
    Bateman, E. D.
    O'Byrne, P. M.
    Lotvall, J.
    Woodcock, A.
    Medley, H.
    Forth, R.
    Jacques, L.
    ALLERGY, 2014, 69 (11) : 1522 - 1530
  • [33] THE EFFECT OF COMBINATION TREATMENT WITH LOW-INTENSITY SHOCKWAVE THERAPY AND TADALAFIL ON MILD AND MILD-TO-MODERATE ERECTILE DYSFUNCTION: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL
    Mykoniatis, I
    Pyrgidis, N.
    Zilotis, F.
    Fournaraki, A.
    Kapoteli, V
    Kalyvianakis, D.
    Hatzichristou, D.
    JOURNAL OF SEXUAL MEDICINE, 2022, 19 (05): : S186 - S186
  • [34] A Phase III, Placebo-Controlled, Double-Blind, Randomized Trial of Tramiprosate in the Clinical Management of Patients with Mild-to-Moderate Alzheimer's Disease (the Alphase Study)
    Aisen, Paul
    Gauthier, Serge
    Ferris, Steven
    Garceau, Denis
    Saumier, Daniel
    Duong, Anh
    Sampalis, John
    NEUROLOGY, 2009, 72 (11) : A271 - A271
  • [35] Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity
    Smith, IG
    Goulder, MA
    JOURNAL OF FAMILY PRACTICE, 2001, 50 (06): : 505 - 512
  • [36] CLINICAL, PATHOLOGICAL AND IMMUNOHISTOCHEMICAL EFFECTS OF ARSENICAL-FERRUGINOUS SPA WATERS ON MILD-TO-MODERATE PSORIATIC LESIONS: A RANDOMIZED PLACEBO-CONTROLLED STUDY
    Borroni, G.
    Brazzelli, V.
    Fornara, L.
    Rosso, R.
    Paulli, M.
    Tinelli, C.
    Ciocca, O.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2013, 26 (02) : 495 - 501
  • [37] A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19
    Rossignol, Jean-Francois
    Bardin, Matthew C.
    Fulgencio, Jessica
    Mogelnicki, Dena
    Brechot, Christian
    ECLINICALMEDICINE, 2022, 45
  • [38] A randomized, placebo-controlled trial of oral itraconazole in scalp psoriasis
    Jury, CS
    McHugh, L
    Shankland, GS
    Burden, AD
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2000, 11 (02) : 85 - 89
  • [39] Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
    Piette, Francois
    Belmin, Joel
    Vincent, Helene
    Schmidt, Nicolas
    Pariel, Sylvie
    Verny, Marc
    Marquis, Caroline
    Mely, Jean
    Hugonot-Diener, Laurence
    Kinet, Jean-Pierre
    Dubreuil, Patrice
    Moussy, Alain
    Hermine, Olivier
    ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (02)
  • [40] Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
    François Piette
    Joël Belmin
    Hélène Vincent
    Nicolas Schmidt
    Sylvie Pariel
    Marc Verny
    Caroline Marquis
    Jean Mely
    Laurence Hugonot-Diener
    Jean-Pierre Kinet
    Patrice Dubreuil
    Alain Moussy
    Olivier Hermine
    Alzheimer's Research & Therapy, 3
12345